Replies to post #462612 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

ATLnsider did of great job of linking his sources. Are you able to provide the basis to your statement? Your statements seem to be at odds with what the relevant doctors in these studies have stated. Just fyi - these combo trials will make the survival data even better. LL wasn't saying that DCVax-L alone didn't help, but rather that it did help and with the combo it would help even MORE.

Have a good one Hope.

[ATLnsider]

Hopeforthefuture3, I will go with what Dr. Liau and Dr. Ashkan said: "DCVax-L helps all patients, but it does help some patients more than others".

DCVax-L is increasing overall survival (OS) for all GBM patients across the board, regardless of gene type, or methylation status. DCVax-L is an effective cure (5+ years of complete remission) combined with the current SOC for up to 25% to 35% of all GBM patients. But it extends OS for all GBM patients.

Dr. Liau wants to extend 5+ years OS to all GBM patients, so she wants to continue to test the efficacy of DCVax-L combined with Keytruda, Poly ICLC and other treatment options, to see if she can increase the percent of GBM patients who are effectively cured to more than 25% to 35%.

Dr. Liau wants to cure 100% of GBM patients. In order for these additional patients to be effectively cured, they will have to have DCVax-L as a core or foundational part of their treatment regimen. All other adjuvant treatment options (checkpoint inhibitors, Poly ICLC, etc.) are optional or in addtion to DCVax-L.

You may not appreciate your life being extended for months or years beyond 14 to 16 months, but most GBM patients, their families and loved ones do appreciate additional months or years of OS. Even if it the OS is less than 5 years.

This gives me an excuse to re-post the Table I put together last year, that compared the OS of the 5 external control arms (ECAs) that Dr. Linda Liau presented in her talk last year. Even with the DCVax-L blended and blinded data, you can see the significant improvement in OS for both methylated and unmythelated GBM patients. You can also see the significant increase in 2-Year, and 3-Year survival for all GBM patients treated with DCVax-L compared to those treated with the current SOC only: